ATRA logo

Atara Biotherapeutics (ATRA) Company Overview

Profile

Full Name:

Atara Biotherapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 16, 2014

Indexes:

Not included

Description:

Atara Biotherapeutics, Inc. is a biotechnology company that is developing new methods of treating patients with cancer, autoimmune, and viral diseases. The company specializes in allogeneic T-cell immunotherapy. It was founded in 2012 and is headquartered in San Francisco, California. The company's priority programs/strategies are: - Tab-cel: an advanced T-cell immunotherapy in Phase 3 clinical development, designed for patients with Epstein-Barr virus. - ATA188: T-cell immunotherapy targeting EBV antigens, considered important for potential treatment of multiple sclerosis. - ATA2271/ATA3271: immunotherapy for patients with hematologic malignancies, solid tumors, and viral diseases. - ATA3219: immunotherapy aimed at treating patients with B-cell lymphomas.

Key Details

Price

$10.30

Annual Revenue

$8.57 M(-86.51% YoY)

Annual EPS

-$65.25(-16.52% YoY)

Annual ROE

-2014.86%

Beta

1.86

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 20, 2024

Analyst ratings

Recent major analysts updates

Jan 22, 25 HC Wainwright & Co.
Neutral
Jan 17, 25 Canaccord Genuity
Buy
Dec 20, 24 Rodman & Renshaw
Buy
Nov 13, 24 Canaccord Genuity
Buy
Aug 21, 24 HC Wainwright & Co.
Neutral
Aug 16, 24 Mizuho
Outperform
Aug 13, 24 Canaccord Genuity
Buy
Jul 17, 24 Goldman Sachs
Sell
May 22, 24 HC Wainwright & Co.
Neutral
Apr 1, 24 Stifel
Hold

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect
ATRA
accessnewswire.comFebruary 6, 2025

NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
ATRA
accessnewswire.comFebruary 5, 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc.("Atara" or the "Company") (NASDAQ:ATRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
ATRA
accessnewswire.comFebruary 4, 2025

LOS ANGELES, CA / ACCESS Newswire / February 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect
ATRA
accessnewswire.comFebruary 2, 2025

NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.

INVESTOR ALERT: The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud
INVESTOR ALERT: The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud
INVESTOR ALERT: The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud
ATRA
accessnewswire.comFebruary 1, 2025

LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
ATRA
accessnewswire.comFebruary 1, 2025

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation
ATRA
accessnewswire.comJanuary 31, 2025

NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.

Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
ATRA
accessnewswire.comJanuary 29, 2025

LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

FAQ

  • What is the ticker symbol for Atara Biotherapeutics?
  • Does Atara Biotherapeutics pay dividends?
  • What sector is Atara Biotherapeutics in?
  • What industry is Atara Biotherapeutics in?
  • What country is Atara Biotherapeutics based in?
  • When did Atara Biotherapeutics go public?
  • Is Atara Biotherapeutics in the S&P 500?
  • Is Atara Biotherapeutics in the NASDAQ 100?
  • Is Atara Biotherapeutics in the Dow Jones?
  • When was Atara Biotherapeutics's last earnings report?
  • When does Atara Biotherapeutics report earnings?
  • Should I buy Atara Biotherapeutics stock now?

What is the ticker symbol for Atara Biotherapeutics?

The ticker symbol for Atara Biotherapeutics is NASDAQ:ATRA

Does Atara Biotherapeutics pay dividends?

No, Atara Biotherapeutics does not pay dividends

What sector is Atara Biotherapeutics in?

Atara Biotherapeutics is in the Healthcare sector

What industry is Atara Biotherapeutics in?

Atara Biotherapeutics is in the Biotechnology industry

What country is Atara Biotherapeutics based in?

Atara Biotherapeutics is headquartered in United States

When did Atara Biotherapeutics go public?

Atara Biotherapeutics's initial public offering (IPO) was on October 16, 2014

Is Atara Biotherapeutics in the S&P 500?

No, Atara Biotherapeutics is not included in the S&P 500 index

Is Atara Biotherapeutics in the NASDAQ 100?

No, Atara Biotherapeutics is not included in the NASDAQ 100 index

Is Atara Biotherapeutics in the Dow Jones?

No, Atara Biotherapeutics is not included in the Dow Jones index

When was Atara Biotherapeutics's last earnings report?

Atara Biotherapeutics's most recent earnings report was on Nov 12, 2024

When does Atara Biotherapeutics report earnings?

The next expected earnings date for Atara Biotherapeutics is Mar 28, 2025

Should I buy Atara Biotherapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions